ArticleInternational journal of ophthalmology2026
JNK inhibitor SP600125 alleviates TGF-β2-induced epithelial-mesenchymal transition in RPE cell
Article in International journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo explore the effect of SP600125, a c-Jun N-terminal kinases (JNK) inhibitor, on epithelial-mesenchymal transition (EMT) in retinal pigment epithelial (RPE) cell caused by transforming growth factor-beta 2 (TGF-β2).
methodsHuman RPE cell line (ARPE-19) cells were treated with TGF-β2 and JNK inhibitor SP600125
resultsTGF-β2 significantly enhanced viability, migration, and proliferation in ARPE-19 cells, induced phosphorylation of TGF-βR2, Smad2/3, JNK, and c-Jun, and upregulated α-SMA, N-cadherin, and vimentin expression. SP600125 inhibited these cellular processes and reduced the expression/phosphorylation of the above proteins; notably, it blocked TGF-β2-induced effects, including cell viability, migration, proliferation, phosphorylation of TGF-βR2, Smad2/3, JNK, and c-Jun, as well as upregulation of α-SMA, N-cadherin, and vimentin.
conclusionJNK inhibitor SP600125 suppresses TGF-β2-induced the increases in cell viability, migration, proliferation, and EMT in RPE cells
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.